{"entity":{"id":"susan-domchek","kind":"person","name":"Susan M. Domchek","aka":[],"tldr":"Leads the world's first centre dedicated to BRCA-related cancers and the trials of PARP inhibitors plus immunotherapy.","summary":"Susan M. Domchek is Executive Director of the Basser Center for BRCA at the Abramson Cancer Center, University of Pennsylvania. She leads the world's first centre dedicated to BRCA-related cancers and is known for trials combining PARP inhibitors with immunotherapy, including MEDIOLA with olaparib plus durvalumab, and for analyses of PARP-inhibitor resistance and reversion in germline BRCA carriers. Her selected paper reports the MEDIOLA study of olaparib and durvalumab in germline BRCA-mutated metastatic breast cancer. Her work spans hereditary breast, ovarian and pancreatic cancer and germline testing.","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Susan_Domchek","links":[{"label":"Basser Center","url":"https://www.basser.org"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Domchek%20SM%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["tnbc","breast-hr-positive","ovarian","pancreatic"],"sections":[],"technologies":["germline-testing"],"targets":["brca","parp"],"drugs":["olaparib"],"companies":[],"institutions":["penn-abramson"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Executive Director, Basser Center for BRCA","institutionId":"penn-abramson","specialisms":["BRCA1/2","Hereditary cancer","PARP inhibitors"],"profiles":[{"label":"Basser Center","url":"https://www.basser.org"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Domchek%20SM%5BAuthor%5D"}],"papers":[{"title":"Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA)","journal":"Lancet Oncology","year":2020,"url":"https://doi.org/10.1016/S1470-2045(20)30324-7","doi":"10.1016/S1470-2045(20)30324-7"},{"title":"OlympiA: a year of olaparib after surgery for BRCA-mutated, high-risk early breast cancer","journal":"New England Journal of Medicine","year":2021,"url":"https://doi.org/10.1056/NEJMoa2105215","doi":"10.1056/NEJMoa2105215"},{"title":"PROSE consortium: preventive surgery lowers cancer and death in BRCA1 and BRCA2 carriers","journal":"JAMA","year":2010,"url":"https://doi.org/10.1001/jama.2010.1237","doi":"10.1001/jama.2010.1237"}],"orcid":"0000-0002-5914-7272"},"route":"/people/susan-domchek/","neighbours":{"cancer":[{"id":"brca-palb2-pdac","kind":"cancer","name":"BRCA or PALB2-mutant pancreatic ductal adenocarcinoma","route":"/cancers/brca-palb2-pdac/"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"technology":[{"id":"germline-testing","kind":"technology","name":"Germline (hereditary) testing","route":"/technologies/germline-testing/"}],"target":[{"id":"brca","kind":"target","name":"BRCA1 / BRCA2 (HRD)","route":"/targets/brca/"},{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/"}],"drug":[{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/"}],"institution":[{"id":"penn-abramson","kind":"institution","name":"Abramson Cancer Center, University of Pennsylvania","route":"/institutions/penn-abramson/"}],"person":[{"id":"angelina-jolie","kind":"person","name":"Angelina Jolie","route":"/people/angelina-jolie/"}],"paper":[{"id":"paper-olympia-nejm-2021","kind":"paper","name":"OlympiA: a year of olaparib after surgery for BRCA-mutated, high-risk early breast cancer","route":"/key-papers/paper-olympia-nejm-2021/"},{"id":"paper-brca-risk-reducing-surgery-jama-2010","kind":"paper","name":"PROSE consortium: preventive surgery lowers cancer and death in BRCA1 and BRCA2 carriers","route":"/key-papers/paper-brca-risk-reducing-surgery-jama-2010/"}]}}